AQST - Piper starts Aquestive at overweight cites allergy reaction treatment
2024-04-11 12:38:15 ET
More on Aquestive Therapeutics
- Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024
- Aquestive Therapeutics, Inc. (AQST) Q4 2023 Earnings Call Transcript
- Aquestive Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation
- Aquestive Therapeutics slumps 13%, prices $75M offering
- Aquestive Therapeutics reports mixed Q4 results; initiates FY24 outlook